GlassScriptPhysician profile
Joy L Becker
NPI 1396863874
$7,230.06
in general payments reported to CMS, 2019-2025
28 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.04 · 2023: $2,742 · 2024: $1,329 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314 · Travel and Lodging: $1,700 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.82 |
| Travel and Lodging | $1,699.83 |
| Education | $170.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $2,741.93 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $782.06 | 2024-2025 | Tezspire |
| Genzyme Corporation | $691.70 | 2024-2025 | |
| Pharming Healthcare, INC. | $370.59 | 2024-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $340.34 | 2021-2025 | Takhzyro, Cuvitru |
| Csl Behring | $313.19 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $295.12 | 2025 | |
| Grifols USA, LLC | $252.12 | 2024-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $209.00 | 2024-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $167.56 | 2025 | Orladeyo |
| Optinose US, INC. | $139.90 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $103.71 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $95.99 | 2025 | |
| Lilly USA, LLC | $85.61 | 2024-2025 | Ebglyss |
| Octapharma USA, INC. | $79.31 | 2024-2025 | Cutaquig |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $74.90 | 2024-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $71.98 | 2024 | Arexvy, Trelegy Ellipta, Nucala |
| Ionis Pharmaceuticals, INC. | $56.28 | 2025 | Dawnzera |
| Genentech USA, INC. | $51.31 | 2024-2025 | Xolair |
| Organon LLC | $51.25 | 2025 | Vtama |
| Leo Pharma INC. | $48.52 | 2025 | Adbry, Anzupgo |
| Kedrion Biopharma, INC. | $41.99 | 2025 | Gammaked, Koate, Kedrab |
| Cycle Pharmaceuticals INC | $38.94 | 2024 | Sajazir |
| Azurity Pharmaceuticals, INC. | $30.88 | 2025 | Alvesco |
| Dermavant Sciences, INC. | $25.70 | 2024 | Vtama |
| Greer Laboratories, INC. | $25.48 | 2024 | Oralair |
| Amgen INC. | $22.76 | 2025 | Tezspire |
| Kaleo, INC. | $21.94 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.